Overview

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Canada, Inc.
Treatments:
Mandelic Acids
Oxybutynin
Solifenacin Succinate